Pacira Pharmaceuticals (NASDAQ:PCRX) Just Hit With Downgrade From Canaccord Genuity. Will Other Analysts Also Downgrade the Stock?

January 18, 2018 - By Louis Casey

  Pacira Pharmaceuticals (NASDAQ:PCRX) Just Hit With Downgrade From Canaccord Genuity. Will Other Analysts Also Downgrade the Stock?

Investors sentiment decreased to 1.39 in 2017 Q3. Its down 0.23, from 1.62 in 2017Q2. It turned negative, as 35 investors sold Pacira Pharmaceuticals, Inc. shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported.

State Street Corporation has invested 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Marsico Cap Mngmt Lc has 0.06% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Hodges Capital Management holds 0.02% or 7,000 shares. Nuveen Asset Ltd Liability Co reported 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Schroder Invest Management Group holds 947,405 shares or 0.06% of its portfolio. Clough Capital Partners Lp, a Massachusetts-based fund reported 183,800 shares. Granahan Inv Management Incorporated Ma has invested 0.53% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Penn Cap Mngmt Inc holds 274,842 shares. Rhumbline Advisers owns 50,179 shares. Baillie Gifford & owns 0.02% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 320,582 shares. Swiss Fincl Bank holds 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 67,100 shares. Pnc Financial Svcs Grp reported 7,770 shares or 0% of all its holdings. Westfield Capital Management Co Lp holds 0.37% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 1.29M shares. Spectrum Management Group invested in 0.05% or 4,418 shares. Tiaa Cref Investment Mngmt Lc owns 188,919 shares.

Since August 15, 2017, it had 0 buys, and 5 insider sales for $2.39 million activity. HASTINGS PAUL J sold $37,741 worth of stock or 1,044 shares. $1.16 million worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares were sold by STACK DAVID M. 3,461 shares were sold by Williams Kristen Marie, worth $127,192.

Pacira Pharmaceuticals (NASDAQ:PCRX) Receives a Downgrade

The stock rating of Pacira Pharmaceuticals (NASDAQ:PCRX) was lowered by equity research analysts at Canaccord Genuity to a “Hold”. This has been announced in a note sent to clients and investors on Sunday, 29 October. Canaccord Genuity after the upgrade has a $33.0 price target on the shares, which would suggest a possible downside of -16.67 %.

Investors sentiment decreased to 1.39 in 2017 Q3. Its down 0.23, from 1.62 in 2017Q2. It turned negative, as 35 investors sold Pacira Pharmaceuticals, Inc. shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported.

State Street Corporation has invested 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Marsico Cap Mngmt Lc has 0.06% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Hodges Capital Management holds 0.02% or 7,000 shares. Nuveen Asset Ltd Liability Co reported 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Schroder Invest Management Group holds 947,405 shares or 0.06% of its portfolio. Clough Capital Partners Lp, a Massachusetts-based fund reported 183,800 shares. Granahan Inv Management Incorporated Ma has invested 0.53% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Penn Cap Mngmt Inc holds 274,842 shares. Rhumbline Advisers owns 50,179 shares. Baillie Gifford & owns 0.02% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 320,582 shares. Swiss Fincl Bank holds 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 67,100 shares. Pnc Financial Svcs Grp reported 7,770 shares or 0% of all its holdings. Westfield Capital Management Co Lp holds 0.37% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 1.29M shares. Spectrum Management Group invested in 0.05% or 4,418 shares. Tiaa Cref Investment Mngmt Lc owns 188,919 shares.

Since August 15, 2017, it had 0 buys, and 5 insider sales for $2.39 million activity. HASTINGS PAUL J sold $37,741 worth of stock or 1,044 shares. $1.16 million worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares were sold by STACK DAVID M. 3,461 shares were sold by Williams Kristen Marie, worth $127,192.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 21 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $55.67’s average target is 40.58% above currents $39.6 stock price. Pacira Pharmaceuticals had 80 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 22 by Canaccord Genuity. The company was initiated on Tuesday, April 19 by Mizuho. The rating was maintained by Jefferies with “Buy” on Wednesday, October 25. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Underperform” rating by BMO Capital Markets on Wednesday, June 29. BMO Capital Markets maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Wednesday, November 8 with “Hold” rating. The stock has “Buy” rating by Mizuho on Thursday, November 3. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Outperform” rating by Wedbush on Wednesday, October 19. As per Friday, January 29, the company rating was upgraded by Bank of America. The company was maintained on Tuesday, July 25 by Canaccord Genuity. The firm earned “Neutral” rating on Monday, August 21 by Janney Capital.

The stock decreased 1.74% or $0.7 during the last trading session, reaching $39.6. About 413,471 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 12.40% since January 18, 2017 and is uptrending. It has underperformed by 4.30% the S&P500.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on March, 7. They expect $-0.08 earnings per share, up 33.33 % or $0.04 from last year’s $-0.12 per share. After $-0.11 actual earnings per share reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.61 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

More recent Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news were published by: Globenewswire.com which released: “Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million” on January 04, 2018. Also Globenewswire.com published the news titled: “WellStar Health System and Pacira Pharmaceuticals Announce Partnership to …” on January 08, 2018. Globenewswire.com‘s news article titled: “Pacira Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare …” with publication date: January 03, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.